Avadel launch­es quick start to nar­colep­sy drug’s mar­ket­ing af­ter long road to ap­proval

Avadel Phar­ma­ceu­ti­cals fired up its mar­ket­ing en­gine and de­buted ad­ver­tis­ing for its nar­colep­sy drug Lum­ryz just weeks af­ter its full FDA ap­proval in May. But it wasn’t ex­act­ly the quick turn it might seem, as the bio­phar­ma was work­ing for months in an­tic­i­pa­tion af­ter Lum­ryz’s ten­ta­tive ap­proval last Ju­ly.

As chief com­mer­cial of­fi­cer Richard Kim ex­plained, it like­ly would have tak­en five to six months to get the cam­paign launched if Avadel had got­ten a fall ap­proval as ex­pect­ed. Still, Avadel used its wait­ing time wise­ly to “sharp­en its pen­cils” to prep mar­ket­ing to get off the ground as quick­ly as pos­si­ble.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER